News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CytoDyn Announces Investor Call To Provide Update On Clinical Development Strategy


3/19/2014 7:26:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company will host a live conference call and webcast with the investment community on Tuesday, March 25, 2014 at 1:30 p.m. PT to provide an update on the Company’s clinical development strategy for lead product candidate, PRO 140, including progress with its preparations for its treatment substitution Phase 2b study in patients with Human Immunodeficiency Virus (HIV).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
CytoDyn
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES